Foreign institutional investors (FIIs) have increased shareholding in Lupin to 34.69% at the end of March 2015 quarter from 31.77% in December 31, 2014. On the other hand, domestic institutional investors (DIIs) have reduced shareholding in the company to 8.67% at the end of March 2015 quarter from 10.73% as on December 31, 2014. Meanwhile, Non Institutions were holding 10.01 percent stake at the end of March 2015 quarter, down 83 basis points from 10.84 percent as on December 31, 2014.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.
